New Vaccine Shows 90% Success Rate In Pancreatic Cancer Prevention

Pancreatic cancer vaccine shows promise in first human trial, preventing disease in high-risk patients

A pancreatic cancer vaccine called mKRAS-VAX triggered a KRAS mutation-targeted immune response in 90% of participants in a Johns Hopkins phase 1 trial.

New Vaccine Shows 90% Success Rate In Pancreatic Cancer Prevention

A preventative pancreatic cancer vaccine triggered immune responses in 90% of participants & was linked to precancerous lesion shrinkage in new trial.

Vaccine to prevent pancreatic cancer passes first test in humans

An anticancer vaccine targeting a common genetic driver of pancreatic cancer was shown to be safe in an early clinical trial, with the results also suggesting it triggered the intended immune response and could potentially intercept the disease. According to the researchers, the experimental vaccine is designed to generate an immune response against a protein called KRAS, which helps regulate cell growth and is thought to play a key role in panc…

First-in-Human mKRAS Vaccine Elicits Durable T-Cell Responses in High-Risk PDAC

A peptide vaccine targeting KRAS variants was safe and produced durable T-cell responses in individuals with hereditary predisposition to pancreatic ductal adenocarcinoma.